Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth concerns and late-stage pipeline limitations as headwinds for the ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

There are many problems with the plan. It ignores the fact, for instance, that generic drugs, which make up 90% of ...

Merck is still plugging away with Keytruda though, and has two phase 3 trials on the go – the KEYNOTE-641 in post-hormonal therapy metastatic CRPC patients, and KEYNOTE-991 in metastatic hormone ...